An interventional study of Echocardiography and ECG screening in Heart Failure, Atrial Fibrillation and Healthy Ageing, sponsored by Monash University. Active, not recruiting at 2 sites in Australia. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Monash University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.
Among the 167 studies in Heart Failure with a site in Australia, this one is the 67th largest by enrollment of the 135 interventional ones that give a count, is one of 4 that started in 2019, is one of 57 with no phase, reaches primary completion later than 18 of the 40 other live ones, and was the 122nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, United States, Argentina and 29 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Australia, Austria, Czechia and 10 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Argentina and 24 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Australia, Bulgaria, Croatia and 4 more countries
Ages 18+
EBR Systems, Inc. · Sites in Australia
Ages 22+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 70 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 26 · Phase 3 47 · Phase 4 8
First in 1983; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 369 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 350 across the 135 interventional studies, 608 across the 31 observational. Of the 116 that completed or were terminated, 59 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 167 have an industry lead sponsor. The 10 most frequent:
Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.
Monash University has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
10 of the studies in Heart Failure with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT04536870Monash UniversityStatins in Reducing Events in the Elderly (STAREE) Heart Sub-study | 2026-12 |
| NCT03093961Corvia MedicalREDUCE LAP-HFREF TRIAL | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 167 studies in Heart Failure with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing (myocardial dysfunction). This will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.
STAREE-HEART is an ancillary study nested in the Statins in Reducing Events in the Elderly (STAREE) double-blind randomised placebo-controlled trial. STAREE is investigating whether statins can prolong good health and maintain independence amongst older people and is enrolling men and women 70 years of age and over who are free from cardiovascular disease, diabetes and dementia. STAREE-HEART will recruit a subset of STAREE participants before they are randomised to STAREE study drug. STAREE-HEART will involve an additional suite of cardiac assessments in these participants and will provide detailed information about the clinical effect of statins on myocardial function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in STAREE trial randomised to statin
Diagnostic Test: Echocardiography · Diagnostic Test: ECG screening
Participants in STAREE trial randomised to placebo
Diagnostic Test: Echocardiography · Diagnostic Test: ECG screening
Ultrasound of heart
Also known as: Global longitudinal strain
Single lead ECG screening twice daily for two weeks
Also known as: Alivecor
12-lead ECG screening
Also known as: 12-lead ECG
Global longitudinal strain (GLS) measured via transthoracic echocardiography.
Change in global longitudinal strain.
Time frame: 3 years
Atrial fibrillation (AF) measured via single lead handheld ECG recordings.
Development of new AF.
Time frame: 3 years
Wavelet analysis via 12-lead ECG with Energy Waveform displays.
Increases detection of Heart Failure (HF).
Time frame: 3 years
Atrial strain
On echocardiography
Time frame: Baseline to 3 year
N- Terminal-pro-Brain Natriuretic Peptide (NT pro BNP)
Predictor of heart failure
Time frame: Baseline to 3 year
Vascular Endothelial Growth Factor (VEG-F)
Endothelial marker
Time frame: Baseline to 3 year
Intercellular Adhesion Molecule 1 (ICAM-1)
Endothelial marker
Time frame: Baseline to 3 year
C-reactive protein
Inflammatory biomarker
Time frame: Baseline to 3 year
Interleukin-6
Inflammatory biomarker
Time frame: Baseline to 3 year
Tumour Necrosis Factor alpha (TNF alpha)
Inflammatory biomarker
Time frame: Baseline to 3 year
Matrix metalloproteinase-9 (MMP-9)
Fibrosis marker
Time frame: Baseline to 3 year
Tumour-derived protein tissue inhibitor of metalloproteinases-1 (TIMP-1)
Fibrosis marker
Time frame: Baseline to 3 year
C-telopeptide of type I collagen (CTX I)
Fibrosis marker
Time frame: Baseline to 3 year
Procollagen III N-terminal propeptide (PIIINP).
Fibrosis marker
Time frame: Baseline to 3 year
Plan to share: No — On completion of the trial, and after publication of the primary and secondary outcomes of the study, requests for access to de-identified data (to be provided through a secure online environment) may be submitted to the researchers located at the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 84 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Monash University